DexCom (NASDAQ:DXCM) had its price target boosted by investment analysts at Piper Sandler from to in a report issued on Friday, The Fly reports.

A number of other equities analysts also recently commented on the stock. Bank of America restated a “buy” rating and set a $250.00 price objective (up from $220.00) on shares of DexCom in a research note on Wednesday, December 18th. Stephens increased their price objective on shares of DexCom from $255.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday. Cowen increased their price objective on shares of DexCom from $250.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday. Jefferies Financial Group increased their price objective on shares of DexCom from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Oppenheimer increased their price objective on shares of DexCom from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Friday. Seven analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $256.00.

Shares of DexCom stock traded up $31.70 during trading hours on Friday, reaching $283.91. 3,359,198 shares of the company’s stock were exchanged, compared to its average volume of 827,010. The company has a 50 day moving average of $234.38 and a two-hundred day moving average of $190.54. DexCom has a fifty-two week low of $107.44 and a fifty-two week high of $295.00. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41. The stock has a market cap of $22.41 billion, a P/E ratio of -145.59 and a beta of 0.80.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $1.15 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.41. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The company had revenue of $462.80 million during the quarter, compared to the consensus estimate of $457.00 million. As a group, analysts expect that DexCom will post 1.43 earnings per share for the current fiscal year.

In other news, EVP Richard Doubleday sold 1,533 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $217.56, for a total value of $333,519.48. Following the sale, the executive vice president now directly owns 48,444 shares of the company’s stock, valued at approximately $10,539,476.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven Robert Pacelli sold 1,532 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $213.17, for a total transaction of $326,576.44. Following the completion of the sale, the executive vice president now directly owns 48,444 shares in the company, valued at $10,326,807.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,427 shares of company stock worth $10,539,425. 0.88% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in DXCM. Renaissance Technologies LLC raised its holdings in DexCom by 1,164.0% in the 4th quarter. Renaissance Technologies LLC now owns 700,243 shares of the medical device company’s stock valued at $153,171,000 after acquiring an additional 644,843 shares during the period. Fred Alger Management LLC raised its holdings in DexCom by 66.3% in the 4th quarter. Fred Alger Management LLC now owns 752,206 shares of the medical device company’s stock valued at $164,538,000 after acquiring an additional 299,754 shares during the period. Beacon Investment Advisory Services Inc. raised its holdings in DexCom by 2,859.7% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 260,451 shares of the medical device company’s stock valued at $56,971,000 after acquiring an additional 251,651 shares during the period. First Trust Advisors LP raised its holdings in DexCom by 358.1% in the 3rd quarter. First Trust Advisors LP now owns 279,121 shares of the medical device company’s stock valued at $41,656,000 after acquiring an additional 218,188 shares during the period. Finally, Great Point Partners LLC bought a new position in DexCom in the 3rd quarter valued at about $22,575,000. 97.85% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: What is the market perform rating?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.